Has the Australian Biotech Industry valuation changed over the past few years?

Investors are optimistic on the Australian Biotechs industry, and appear confident in long term growth rates. The industry is trading at a PE ratio of 51.7x which is higher than its 3-year average PE of 41.6x. The 3-year average PS ratio of 5.4x is higher than the industry's current PS ratio of 3.2x.

Which industries have driven the changes within the Australian Healthcare industry?

There are no additional sub-industries under this industry.

Australian (ASX) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 05 Aug 2026	AU$74.0b	AU$23.5b	AU$1.4b	22.6x	51.7x	3.2x
Fri, 03 Jul 2026	AU$69.3b	AU$23.9b	AU$1.5b	21.9x	47.2x	2.9x
Sun, 31 May 2026	AU$58.3b	AU$22.9b	AU$1.4b	24.1x	41.8x	2.5x
Tue, 28 Apr 2026	AU$75.2b	AU$22.9b	AU$1.4b	23.2x	54.1x	3.3x
Thu, 26 Mar 2026	AU$78.9b	AU$23.7b	AU$1.4b	24.5x	54.5x	3.3x
Sat, 21 Feb 2026	AU$85.5b	AU$23.3b	AU$1.5b	26.7x	57.5x	3.7x
Mon, 19 Jan 2026	AU$97.0b	AU$24.6b	AU$4.0b	18.8x	24.1x	3.9x
Wed, 17 Dec 2025	AU$97.9b	AU$24.8b	AU$4.0b	18.9x	24.2x	4x
Fri, 14 Nov 2025	AU$100.3b	AU$25.0b	AU$4.1b	19.2x	24.5x	4x
Sun, 12 Oct 2025	AU$114.7b	AU$25.3b	AU$4.2b	21.8x	27.6x	4.5x
Tue, 09 Sep 2025	AU$114.7b	AU$24.9b	AU$4.1b	22.7x	28.1x	4.6x
Thu, 07 Aug 2025	AU$143.5b	AU$24.5b	AU$3.9b	44.9x	37.1x	5.9x
Sat, 05 Jul 2025	AU$131.5b	AU$24.3b	AU$3.8b	33.6x	34.4x	5.4x
Mon, 02 Jun 2025	AU$133.9b	AU$24.7b	AU$3.9b	21x	34.3x	5.4x
Wed, 30 Apr 2025	AU$133.5b	AU$24.8b	AU$3.9b	21.1x	34x	5.4x
Fri, 28 Mar 2025	AU$138.5b	AU$25.3b	AU$4.0b	21.6x	34.6x	5.5x
Sun, 23 Feb 2025	AU$142.4b	AU$25.0b	AU$3.8b	22.7x	37.6x	5.7x
Tue, 21 Jan 2025	AU$148.8b	AU$24.8b	AU$3.7b	24.1x	40.1x	6x
Thu, 19 Dec 2024	AU$151.2b	AU$24.3b	AU$3.6b	24.7x	41.6x	6.2x
Sat, 16 Nov 2024	AU$146.5b	AU$23.8b	AU$3.5b	25.7x	41.4x	6.2x
Mon, 14 Oct 2024	AU$155.8b	AU$22.8b	AU$3.4b	28.2x	46.2x	6.8x
Wed, 11 Sep 2024	AU$156.7b	AU$23.1b	AU$3.4b	28.8x	45.8x	6.8x
Fri, 09 Aug 2024	AU$157.9b	AU$22.5b	AU$3.3b	31x	47.7x	7x
Sun, 07 Jul 2024	AU$156.1b	AU$21.9b	AU$3.2b	34.2x	48.8x	7.1x
Tue, 04 Jun 2024	AU$147.0b	AU$22.1b	AU$3.2b	30.9x	45.5x	6.6x
Thu, 02 May 2024	AU$142.3b	AU$22.6b	AU$3.3b	30x	43x	6.3x
Sat, 30 Mar 2024	AU$147.5b	AU$22.5b	AU$3.3b	30.3x	44.7x	6.5x
Mon, 26 Feb 2024	AU$144.9b	AU$22.4b	AU$3.3b	36.6x	43.7x	6.5x
Wed, 24 Jan 2024	AU$149.0b	AU$20.9b	AU$2.8b	34x	53.8x	7.1x
Fri, 22 Dec 2023	AU$143.6b	AU$20.3b	AU$2.7b	34.2x	53.5x	7.1x
Sun, 19 Nov 2023	AU$131.6b	AU$21.1b	AU$2.8b	32x	46.9x	6.3x
Tue, 17 Oct 2023	AU$123.8b	AU$21.8b	AU$2.9b	29.8x	43.2x	5.7x
Thu, 14 Sep 2023	AU$137.7b	AU$21.4b	AU$2.8b	32.4x	49.1x	6.4x
Sat, 12 Aug 2023	AU$136.3b	AU$18.4b	AU$2.4b	38.4x	57.1x	7.4x


AU Market	2.02%
Healthcare	4.63%
Biotech	6.99%
Biotech	6.99%

Company	Last Price	7D	1Y	Valuation
CSL CSL	AU$130.66	2.0% +AU$1.2b	-51.5%	PE31.6x
PYC PYC Therapeutics	AU$2.10	29.2% +AU$467.2m	61.5%	PS100.5x
MSB Mesoblast	AU$2.13	4.4% +AU$117.0m	-12.3%	PS29.8x
TLX Telix Pharmaceuticals	AU$14.72	1.5% +AU$74.8m	-20.8%	PS4.4x
DXB Dimerix	AU$0.29	20.8% +AU$30.0m	-40.8%	PS23.5x

Announcement • Jul 20

Actinogen Medical Announces Results from Xanamem Phase 2 Depression Proof-Of-Concept Trial

Actinogen Medical announced that results from its proof-of-concept trial, entitled “A phase 2 randomised, double-blind, placebo-controlled trial of emestedastat in patients with major depressive disorder (MDD) and cognitive impairment (CI)” have just been published as a peer-reviewed article in the British Journal of Psychiatry. Key conclusions from the article: Xanamem (emestedastat) may be a novel antidepressant and worthy of further investigation (further Xanamem trials in MDD will depend on future funding and partnership arrangements). In contrast to the previously held belief that cognition improves along with depressive symptoms, there was no correlation of improvement in cognition with improvement in depression. Unique trial design studied participants with both measurable cognitive impairment and depression to assess potential Xanamem benefit on both - in other aspects the trial was a standard phase 2a design for MDD using a six-week treatment period with a further four weeks of blinded follow up. Enrolled 165 participants characterized as having “difficult-to-treat” MDD, with clinically significant residual MDD and measurable CI, most of whom were on another anti-depressant in addition to the trial treatment. Anti-depressant benefit vs. placebo was maximal at Week 10 (2.7 MADRS points, p < 0.05) during the blinded follow up phase. A similar benefit was seen in key subgroups including the 46% of patients who were on background SSRI medication (4.2 MADRS points, p < 0.05). The observed “lag” in Xanamem benefit to improve depression scores is consistent with the known timeframe of onset and reversal of chronic cortisol-related side effects, e.g. when starting or stopping chronic prednisolone treatment. A larger placebo group improvement in CI symptoms than previously reported was observed, with no evidence of Xanamem treatment benefit. Xanamem was safe and well-tolerated. The XanaMIA Phase 2b/3 Alzheimer’s disease trial is a double-blind, 36-week treatment, placebo-controlled, parallel group design trial in 247 patients with mild to moderate AD and progressive disease, determined by clinical criteria and confirmed by an elevated level of the pTau181 protein biomarker in blood. Patients receive Xanamem 10 mg or placebo, once daily, and its ability to slow progression of Alzheimer’s disease is assessed with a variety of endpoints. The primary endpoint of the trial is the internationally-recognized CDR-SB (Clinical Dementia Rating scale – Sum of Boxes). The trial is being conducted in Australia and the US and is now closed to participant recruitment. It has passed an independent Data Monitoring Committee safety and efficacy futility review and final topline results are expected in November 2026. The XanaMIA-OLE Alzheimer’s disease open-label extension is an open-label phase of up to 25 months treatment where all participants will receive active Xanamem 10 mg once daily. The trial evaluates safety and a limited number of efficacy endpoints such as the CDR-SB. The trial commenced in March 2026 and is open to all former and current participants in the XanaMIA Phase 2b/3 trial. The XanaCIDD Phase 2a depression trial was a double-blind, six-week proof-of-concept, placebo-controlled, parallel group design trial in 167 patients with moderate, treatment-resistant depression and a degree of baseline cognitive impairment. Participants were evenly randomized to receive Xanamem 10 mg once daily or placebo, in most cases in addition to their existing antidepressant therapy, and effects on cognition and depression were assessed. Trial results were reported in August 2024 and showed clinically and statistically significant benefits on depression symptoms with positive effects on the MADRS scale (a validated scale of depression symptom measurement) and the PGI-S (a valid patient reported assessment of depression severity). Cognition improved markedly and to a similar extent in both Xanamem and placebo groups. Xanamem’s novel mechanism is to control elevated levels of cortisol (aka the “stress hormone”) in the brain through the inhibition of the cortisol synthesis enzyme, 11ß-HSD1, without affecting production of cortisol by the adrenal glands which is essential for the body’s normal functioning. Xanamem is a first-in-class, once-a-day pill designed to deliver high levels of cortisol control in key areas of the brain related to Alzheimer’s and other diseases such as the hippocampus and frontal cortex. Chronically elevated cortisol is associated with progression in Alzheimer’s Disease and excess cortisol is known to be toxic to brain cells. Cortisol itself is also associated with depressive symptoms and when targeted via other mechanisms has shown some promise in prior clinical trials. The recent XanaCIDD trial demonstrated clinically and sometimes statistically significant benefits on depressive symptoms, further validating the cortisol control mechanism for the Xanamem 10 mg oral daily dose. The Company has studied 11ß-HSD1 inhibition by Xanamem in more than 500 volunteers and patients in eight clinical trials. Xanamem has a promising safety profile and has demonstrated clinical activity in patients with depression, patients with biomarker-positive Alzheimer’s disease and cognitively normal volunteers. High levels of target engagement in the brain with doses as low as 5 mg daily have been demonstrated in a human PET imaging study. Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority.

Australian (ASX) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Consensus EPS estimates upgraded to US$1.56 loss

Amplia Therapeutics Limited Details Preclinical Studies of Narmafotinib In Pancreatic Cancer

Mesoblast Reports Ryoncil Revenue Milestone and Completes Key Phase 3 Enrollment

Telix Pharmaceuticals Limited to Report First Half, 2026 Results on Aug 20, 2026

Clinuvel Pharmaceuticals Ltd Provides Update On SCENESSE In Vitiligo

Price target increased by 7.9% to AU$6.60

Forecast to breakeven in 2029

Aroa Biosurgery Limited Appoints Michael Lynskey as Chief Commercial Officer and A Member of the Executive Leadership Team

Actinogen Medical Announces Results from Xanamem Phase 2 Depression Proof-Of-Concept Trial

New major risk - Share price stability

CEO & Chairperson recently bought AU$189k worth of stock

Racura Oncology Doses First Patient in Harness-1 Phase 1A/B Trial of Rc220 in Combination with Osimertinib for Egfr-Mutant Non-Small Cell Lung Cancer

Algorae Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.024 million.

New major risk - Share price stability

Patrys Limited has filed a Follow-on Equity Offering in the amount of AUD 0.05 million.

Biotron Limited Appoints Graeme Wald as Non-Executive Director, Effective March 30, 2026